In Reply We greatly appreciate the suggestions of Ms Chen and colleagues in response to our recent Viewpoint and concur that vaccine—or even more broadly, immune—certificates to permit people to participate in nonessential activities, such as flying and attending indoor activities (eg, concerts), would be useful to reduce COVID-19 transmission. We also support the use of regular seroprevalence surveillance to assess population immunity. These are part of an optimal approach to COVID-19.

Ezekiel J. Emanuel, MD, PhD
David Michaels, PhD, MPH
Rick A. Bright, PhD

Author Affiliations: Perelman School of Medicine, University of Pennsylvania, Philadelphia (Emanuel); Milken Institute School of Public Health, George Washington University, Washington, DC (Michaels); The Rockefeller Foundation, New York, New York (Bright).

Corresponding Author: Ezekiel J. Emanuel, MD, PhD, Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, 423 Guardian Dr, Blockley Hall, Philadelphia, PA 19104 (zemanuel@upenn.edu).

Conflict of Interest Disclosures: Dr Emanuel reported receipt of personal fees, nonfinancial support, or both from companies, organizations, and professional health care meetings and being a venture partner at Oak HC/FT; a partner at Embedded Healthcare LLC, ReCover Partners LLC, and COVID-19 Recovery Consulting; and an unpaid board member of Village MD and Oncology Analytics. Dr Emanuel owns no stock in pharmaceutical, medical device companies, or health insurers. Dr Michaels reported receipt of grants from the McElhattan Foundation and Institute for New Economic Thinking and personal fees from the Actors’ Equity Association, Axiom, Health Action Alliance, Estée Lauder Companies, and Verily Life Sciences. No other disclosures were reported.


Correction

Incorrect Spelling of Author Name: In the Original Investigation titled “Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals,”1 published in the April 12, 2022, issue of JAMA, an author name was misspelled. In the byline, the third author, “Marguerite R. Ivin, PhD” should have been “Marguerite R. Irvin, PhD.” This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editors: Jody W. Zylke, MD, Deputy Editor; Kristin Walter, MD, Associate Editor.